Huw Morris on Muck Rack

Huw Morris

London
As seen in: Nature, Taylor & Francis Online, The BMJ, JAMA (The Journal of the American Medical Association), Medscape, The American Journal of Human Genetics, The Lancet, King's College London, BJGP (British Journal of General Practice), Monmouthshire County Life and
Neurologist and Researcher, Studying Parkinson's disease, PSP, Motor Neuron Disease and Dementia Researcher ID: B-8527-2008
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Huw

Contact Huw, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

LRRK2 -targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial

|
By Omar S. Mabrouk, Ben Tichler, Eva Thoma, Sara Alexanian, Jingxian Chen, Tzu-Ying Liu, John Annand, Unnati Kapadnis, Kyle Ferber, Yuka Moroishi, Julie M Czerkowicz, Jennifer A. Inra, Ronald B. Postuma, Tanya Gurevich, Pablo Mir, Huw Morris, Jason Aldred, Matthew Brodsky, Aaron Ellenbogen, Christopher M Tolleson, Andrew Siderowf, Charalampos Tzoulis, María Martí, Hien T. Zhao, Holly B. Kordasiewicz, Roger M Lane, Warren D. Hirst, Stephanie Fradette, Danielle Graham, H. Moore Arnold, Beth Hirschhorn, Roy Llorens Arenas, Alan A. Shomo, Kelly E. Glajch, Danielle Larson, Ernest Balaguer
| Nature
Abstract LRRK2 (encoding leucine-rich repeat kinase 2) variants are the most common genetic cause of Parkinson’s disease (PD). Lowering LRRK2 levels and/or inhibiting LRRK2 activity may modify PD-associated neuropathology. BIIB094 (ION859), an antisense oligonucleotide, targets LRRK2 mRNA for degradation. REASON was a first-in-human randomized phase 1 study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal BIIB094 in patients with PD.
Open in Who Shared Issue with article?

Tackling a disease on a global scale, the Global Parkinson’s Genetics Program, GP2: A new generation of opportunities

|
By Cornelis Blauwendraat, Alastair J. Noyce, Ignacio F. Mata, Laurel A. Screven, Sonya B. Dumanis, Njideka U. Okubadejo, Christine Klein, Huw Morris, Andrew Singleton, J. Solle, Ekemini A. Riley, Maria Teresa Periñan
| The American Journal of Human Genetics
Keywords Parkinson disease global genetics global consortium precision medicine What is Parkinson disease? Parkinson disease (PD) refers to a clinical diagnosis with features that correspond to recognizable neuropathological changes at postmortem (i.e., Lewy body pathology and nigrostriatal degeneration).
Open in Who Shared Issue with article?

The LRRK2 p.L1795F variant causes Parkinson’s disease in the European population - npj Parkinson's Disease

|
By Lara M. Lange, Kristin Levine, Hirotaka Iwaki, Katja Lohmann, Luca Marsili, Alberto J Espay, Jessica Martin, Stewart A. Factor, Huw Morris, Cornelis Blauwendraat, Zih-hua Fang
| Nature
Abstract LRRK2-PD represents the most common form of autosomal dominant Parkinson’s disease. We identified the LRRK2 p.L1795F variant in three families and six additional unrelated cases using genetic data from over 50,000 individuals. Carriers with available genotyping data shared a common haplotype. The clinical presentation resembles other LRRK2-PD forms.
Open in Who Shared Issue with article?
See all 28 licensed articles (216 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Huw

Contact Huw, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified